Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision

The big biotech reported that both the FDA as well as the EMA have accepted their application for ozanimod, an experimental therapy for multiple sclerosis.